Multiple Sclerosis Treatment Shows Promising Results Unveiled By Medical Company

In a significant development for the multiple sclerosis (MS) community, Clene Inc. recently unveiled the results of its Phase 2 VISIONARY-MS long-term extension study at the prestigious 2024 American Academy of Neurology (AAN) Annual Meeting. The findings are nothing short of groundbreaking, demonstrating substantial evidence that CNM-Au8®, an investigational therapy, not only aids in the repair and remyelination of damaged neurons but also improves vision and cognition in MS patients. $Clene(CLNN.US)$